IDH1 and neoplasm: GL26-IDH1 host survival was decreased by administration of a very large vaccine dose (2 × 107 GL26 tumor lysate-pulsed DC 2.4 cells), reminiscent of other models of immunotherapy-induced immunosuppression [21, 22] (Fig. 1C).